Category: Publications

Article: Summit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright

Summit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright

Austin Angelo

AnalystRatings, 1 May 2020

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today and set a price target of $4.00. The company’s shares closed last Thursday at $3.75.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 14.2% and a 41.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Collegium Pharmaceutical.

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

Article: H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)

H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)

Jason Carr

AnalystRatings, 1 May 2020

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Insmed (INSM – Research Report) today and set a price target of $52.00. The company’s shares closed last Thursday at $23.00.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 7.7% and a 46.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

Article: H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)

H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)

Christine Brown

SmarterAnalyst, 1 May 2020

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Pluristem (PSTI), with a price target of $15.50. The company’s shares closed last Thursday at $9.17.

According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.7% and a 36.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, IntelGenx Technologies, and Corvus Pharmaceuticals.

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

Article: H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)

H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)

Christine Brown

SmarterAnalyst, 1 May 2020

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CareDx (CDNA), with a price target of $40.00. The company’s shares closed last Thursday at $25.38.

According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.1% and a 43.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

Article: Famed short-seller David Einhorn calls out Tesla’s billing practices again, erasing the stock’s post-earnings gain

Famed short-seller David Einhorn calls out Tesla’s billing practices again, erasing the stock’s post-earnings gain

Business Insider, 30 April 2020

David Einhorn of Greenlight Capital has again taken to Twitter to call out Tesla’s accounting practices in a message directed at CEO Elon Musk.

“Dear Elon, I guess the offer of a factory tour was never serious,” Einhorn, a long-time Tesla bear and short-seller, tweeted Thursday. “I remain curious about your accounts receivable.”

Shares of Tesla pared gains from earlier in the day and traded down as much as 3% following Einhorn’s comments.

Paywall Access to Full Article

Article: Co-Diagnostics Inc. [CODX] stock Reiterated by H.C. Wainwright analyst, price target now $20

Co-Diagnostics Inc. [CODX] stock Reiterated by H.C. Wainwright analyst, price target now $20

Brandon Evans

DBT News, 30 April 2020

Co-Diagnostics Inc. [NASDAQ: CODX] traded at a low on 04/29/20, posting a -8.57 loss after which it closed the day’ session at $12.37. The results of the trading session contributed to over 5099148 shares changing hands. Over the past one week, the price volatility of Co-Diagnostics Inc. stands at 10.98% while the volatility over the past one month is 12.61%.

The market cap for CODX stock reached $332.63 million, with 26.89 million shares outstanding and 20.80 million shares in the current float. Compared to the average trading volume of 12.82M shares, CODX reached a trading volume of 5099148 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

Article: H.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB)

H.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB)

Ryan Adist

SmarterAnalyst, 30 April 2020

H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on PDS Biotechnology (PDSB) today. The company’s shares closed last Wednesday at $0.95, close to its 52-week low of $0.62.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 14.5% and a 43.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

Article: Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright

Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright

Austin Angelo

SmarterAnalyst, 30 April 2020

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (), with a price target of $295.00. The company’s shares closed last Wednesday at $251.05.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.9% and a 48.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

Article: H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)

H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)

Austin Angelo

SmarterAnalyst, 30 April 2020

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Aravive (ARAV), with a price target of $15.00. The company’s shares closed last Thursday at $12.95.